K. Douglas
Serimmune (United States)(US)
Publications by Year
Research Areas
Hematopoietic Stem Cell Transplantation, Childhood Cancer Survivors' Quality of Life, Biomedical Ethics and Regulation, Pancreatic and Hepatic Oncology Research, Platelet Disorders and Treatments
Most-Cited Works
- → Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome(2013)1,539 cited
- → Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data(2010)132 cited
- → Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura(2017)123 cited
- → European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization(2011)65 cited
- → HPC‐A dose prediction on the optia® cell separator based on a benchmark CE2 collection efficiency: Promoting clinical efficiency, minimizing toxicity, and allowing quality control(2015)39 cited
- → Heparin-induced thrombocytopenia type II: A rare but significant complication of plasma exchange(2005)18 cited
- → Comparison of IM Ketorolac Trometamol and Morphine Sulphate for Pain Relief After Cholecystectomy(1991)11 cited
- → Letter to the Editor(2014)4 cited
- PBSC Collection on the Optia Cell Separator Platform: Dose Prediction Based on a Benchmark “CE2” Collection Efficiency is Significantly More Accurate Than “Collect Ratio”-Based Dose Prediction Using Peripheral CD34+ Count Alone(2011)
- Patient and disease characteristics influencing the outcome of mobilization with plerixafor: large compassionate-use analysis by ECOSM (European Consortium for Stem Cell Mobilization)(2011)